<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84902805802</prism:url><dc:identifier>SCOPUS_ID:84902805802</dc:identifier><eid>2-s2.0-84902805802</eid><pubmed-id>24908382</pubmed-id><prism:doi>10.1016/j.tibtech.2014.05.005</prism:doi><dc:title>Therapeutic protein aggregation: Mechanisms, design, and control</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>4</citedby-count><prism:publicationName>Trends in Biotechnology</prism:publicationName><dc:publisher>Elsevier Ltd</dc:publisher><source-id>16146</source-id><prism:issn>18793096</prism:issn><prism:volume>32</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:startingPage>372</prism:startingPage><prism:endingPage>380</prism:endingPage><prism:pageRange>372-380</prism:pageRange><prism:coverDate>2014-01-01</prism:coverDate><dc:creator><author auid="7404402457" seq="1"><ce:initials>C.J.</ce:initials><ce:indexed-name>Roberts C.J.</ce:indexed-name><ce:surname>Roberts</ce:surname><ce:given-name>Christopher J.</ce:given-name><preferred-name><ce:initials>C.J.</ce:initials><ce:indexed-name>Roberts C.</ce:indexed-name><ce:surname>Roberts</ce:surname><ce:given-name>Christopher J.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7404402457</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60023004" id="60023004"/></author></dc:creator><dc:description><abstract original="y" xml:lang="eng"><ce:para>Although it is well known that proteins are only marginally stable in their folded states, it is often less well appreciated that most proteins are inherently aggregation-prone in their unfolded or partially unfolded states, and the resulting aggregates can be extremely stable and long-lived. For therapeutic proteins, aggregates are a significant risk factor for deleterious immune responses in patients, and can form via a variety of mechanisms. Controlling aggregation using a mechanistic approach may allow improved design of therapeutic protein stability, as a complement to existing design strategies that target desired protein structures and function. Recent results highlight the importance of balancing protein environment with the inherent aggregation propensities of polypeptide chains. Â© 2014 Elsevier Ltd.</ce:para></abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84902805802" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84902805802&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84902805802%29" rel="cited-by"/></coredata><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60023004" id="60023004"><affilname>University of Delaware</affilname></affiliation><authors><author auid="7404402457" seq="1"><ce:initials>C.J.</ce:initials><ce:indexed-name>Roberts C.J.</ce:indexed-name><ce:surname>Roberts</ce:surname><ce:given-name>Christopher J.</ce:given-name><preferred-name><ce:initials>C.J.</ce:initials><ce:indexed-name>Roberts C.</ce:indexed-name><ce:surname>Roberts</ce:surname><ce:given-name>Christopher J.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7404402457</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60023004" id="60023004"/></author></authors></abstracts-retrieval-response>
